Record mula sa primary source
FDA's Purple Book lists BLA 125806 (kresladi, marnetegragene autotemcel; Rocket Pharmaceuticals Inc, CBER) as licensed on 2026-03-26.
Rocket Pharmaceuticals ibinenta ang KRESLADI PRV sa halagang $180 milyon
Rocket Pharmaceuticals: KRESLADI PDUFA itinakda sa Marso 28, 2026
Rocket Pharmaceuticals: KRESLADI™ PDUFA itinakda sa Marso 28, 2026
Rocket Pharmaceuticals: Tinanggap ng FDA ang muling pagsumite ng KRESLADI BLA; PDUFA Marso 28, 2026